Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Clinigence Holdings ( (NUTX) ) has provided an update.
On July 8, 2025, Joshua DeTillio, the Chief Operating Officer of Nutex Health, Inc., announced his resignation effective August 8, 2025, to take on a CEO role at another company. His departure is amicable, with no disputes or disagreements involved, and the company’s Board of Directors is actively searching for his replacement.
The most recent analyst rating on (NUTX) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.
Spark’s Take on NUTX Stock
According to Spark, TipRanks’ AI Analyst, NUTX is a Outperform.
Nutex Health’s strong financial performance and impressive earnings call results are the most significant contributors to the overall score. The company’s solid revenue growth, profitability improvements, and strategic expansion plans indicate a promising outlook. The technical indicators suggest some caution, but the undervaluation based on the P/E ratio enhances the stock’s attractiveness.
To see Spark’s full report on NUTX stock, click here.
More about Clinigence Holdings
Average Trading Volume: 192,820
Technical Sentiment Signal: Hold
Current Market Cap: $642.7M
For a thorough assessment of NUTX stock, go to TipRanks’ Stock Analysis page.